RecruitingPhase 4NCT05176379

Endothelial Derived Hyperpolarization Factor and Vascular Control

Endothelial Derived Hyperpolarization Factor and Regulation of Cerebral and Muscle Blood Flow


Sponsor

University of Oklahoma

Enrollment

30 participants

Start Date

Feb 19, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA


Eligibility

Min Age: 18 YearsMax Age: 30 Years

Inclusion Criteria5

  • Normotensive (systolic blood pressure < 130 mmHg and/or diastolic blood pressure < 85 mmHg) individuals
  • Individuals free of cardiovascular disease and metabolic disease
  • Individuals free of any form of autonomic dysfunction
  • Individuals with a BMI under 30 kg/m²
  • Women that are premenopausal with a regular menstrual cycle (26-30 days)

Exclusion Criteria7

  • Smokers, tobacco users (regular use in the last 6 months)
  • Individuals with a blood pressure greater than 130/85
  • Subjects who use Amiodarone, Sulphaphenazole
  • Subjects who use S-warfarin, Tolbutamine, Phenytoin, Lonafarnib
  • Cardiometabolic medication use (e.g. anti-hypertensives, insulin-sensitizing, statins)
  • Sex hormone replacement medical use (e.g. testosterone, estrogen, progesterone)
  • Pregnancy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFluconazole 150 mg

A single acute 150 mg dose


Locations(1)

Department of Health and Exercise Science

Norman, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05176379


Related Trials